Pyxis Oncology Inc

Stock Chart, Company Information, and Scan Results

$1.06(as of Aug 8, 4:00 PM EST)

Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.

Pyxis Oncology Inc Company Information, Fundamentals, and Technical Indicators

Stock Price$1.06
Ticker SymbolPYXS
ExchangeNasdaq
SectorHealthcare
IndustryBiotechnology
Employees44
CountyUSA
Market Cap$65.7M
EBIDTA-80.7M
10-Day Moving Average1.11
P/E Ratio-0.68
20-Day Moving Average1.15
Forward P/E Ratio0.00
50-Day Moving Average1.19
Earnings per Share-1.61
200-Day Moving Average1.60
Profit Margin-Infinity%
RSI41.03
Shares Outstanding61.9M
ATR0.08
52-Week High5.39
Volume379,732
52-Week Low0.83
Most Recent Support Level1.03
Book Value103.1M
Most Recent Resistance Level1.38
P/B Ratio0.63
Upper Keltner1.32
P/S Ratio19.02
Lower Keltner0.98
Debt-to-Equity Ratio1.32
Next Earnings Date08/19/2025
Cash Surplus-1.7M
Next Ex-Dividend DateUnknown

Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat solid tumors. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors. The company is also developing PYX-107, a CD40 agonist with demonstrated anti-cancer activity in patients with several cancer indications, which is in Phase 2 clinical trial for the treatment of tumors, such as soft tissue sarcomas, esophageal and gastroesophageal junction, cancers, and pancreatic ductal adenocarcinoma. It has in-license agreement with Pfizer Inc. to develop and commercialize ADC product candidates, including micvotabart pelidotin and PYX-203, and other ADC product candidates directed to the licensed targets; and Biosion USA, Inc. for development, manufacture, and commercialization of PYX-106, an IO product candidate. Pyxis Oncology, Inc. was incorporated in 2018 and is headquartered in Boston, Massachusetts.

Pyxis Oncology Inc In Our Stock Scanner

As of Aug 11, 2025
example chart graphic
Scan Name: Dragonfly DojiScan Type: Candlestick Pattern Scans
As of ---
example chart graphic
Scan Name: Hammer CandleScan Type: Candlestick Pattern Scans
As of ---
example chart graphic
Scan Name: Low Debt to Equity RatioScan Type: Stock Fundamentals
As of ---
example chart graphic
Scan Name: Low PB RatioScan Type: Stock Fundamentals
As of ---
example chart graphic
Scan Name: Doji CandlesScan Type: Candlestick Pattern Scans
As of ---

Join Our Free Email List

Get emails from us about ways to potentially make money in the stock market.